drugset / Trial / NCT05560360

A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

NCT05560360

Phase 1 Completed 20 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study used a single-dose, open and fixed sequence design to compare the pharmacokinetics in healthy subjects.

Timeline

Start
2022-11-04
Primary completion
2022-12-02
Completion
2023-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject EDRALBRUTINIB Small molecule 100 mg Oral
Subject Efavirenz Other / unclassified 600 mg Oral

Indications